Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 152 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Hemorrhagic Radiation Proctitis Using the Halo System

NCT01103492
Conditions
Pelvic Neoplasms
Interventions
HALO90 Ablation catheter
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Benign Prostatic Hyperplasia
Interventions
Tranexamic Acid (IV), Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years and older · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Uterine Leiomyoma, Uterine Fibroids
Interventions
Relugolix, Estradiol/norethindrone acetate, Placebo for relugolix, Placebo for E2/NETA
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
72
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 61 more
Completed Not applicable Interventional Accepts healthy volunteers

Study Comparing Conventional vs. Robotic-assisted Laparoscopic Hysterectomy

NCT00485355
Conditions
Uterine Fibroids, Menorrhagia, Endometriosis
Interventions
conventional laparoscopic hysterectomy, robotic assisted laparoscopic hysterectomy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Menstruation; Heavy
Interventions
Nighttime Feminine Product
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Menorrhagia
Interventions
Aurora Endometrial Ablation, Rollerball Ablation/Resection
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Chandler, Arizona • Phoenix, Arizona • Newburgh, Indiana + 5 more
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Conditions
Immune Thrombocytopenic Purpura ( ITP ), HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Birth Control, Contraception, Implant, Breakthrough Bleeding, Uterine Bleeding
Interventions
Norethindrone acetate (NTA), Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
14 Years to 48 Years · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Temple, Texas
Conditions
Symptomatic Uterine Fibroids and Adenomyosis
Interventions
IV Ibuprofen, IV Acetaminophen, Intravenous placebo/Intravenous placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Conditions
Heavy Menstrual Bleeding
Interventions
Juveena Hydrogel System
Device
Lead sponsor
Rejoni Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Orange, New Jersey + 1 more
Conditions
Abnormal Uterine Bleeding, Analgesia, Paracervical Block
Interventions
paracervical block, Lidocaine, ketorolac
Procedure · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Menorrhagia
Interventions
Tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
92
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

NCT05862805
Conditions
Menstrual Bleeding, Heavy
Interventions
Sample Collection and Endometrial Biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
52
States / cities
Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more
Completed Not applicable Interventional Accepts healthy volunteers

Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy

NCT02472184
Conditions
Uterine Fibroids, Vaginal Bleeding
Interventions
Office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Laparoscopic Myomectomy
Interventions
Not listed
Lead sponsor
The Advanced Gynecologic Surgery Institute
Other
Eligibility
16 Years to 70 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Naperville, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Menorrhagia
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028), Medroxyprogesterone acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
37
States / cities
Tucson, Arizona • Beverly Hills, California • Carmichael, California + 32 more
Conditions
Uterine Hemorrhage, Menorrhagia
Interventions
Provera, Combination Birth Control pills
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Interventions
Volta System
Device
Lead sponsor
Five Liters, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas